NCT03115099View on ClinicalTrials.gov

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3325656

Administered orally

DRUG

Placebo

Administered orally

DRUG

Liraglutide

Administered subcutaneously

DRUG

Sitagliptin

Administered orally

Trial Locations (2)

117597

For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03115099 - A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter